阿德福韦酯联合双环醇治疗慢性乙型肝炎疗效剖析.docVIP

阿德福韦酯联合双环醇治疗慢性乙型肝炎疗效剖析 　　【摘要】目的：阿德福韦酯联合双环醇治疗慢性乙型肝炎的疗效。方法：选择71例轻中度慢性乙型肝炎患者随机分为2组接受试验，试验组36例，每日口服阿德福韦酯（山东鲁抗辰欣生产，商品名丁贺，以下简称丁贺）10mg，同时每日口服双环醇（北京协和生产）150mg,对照组35例，仅给予每日口服丁贺10mg，2组均连续用药48周，观察治疗前后血清氨基转移酶水平及病毒学标志方面的改变；结果：2组血清氨基转移酶均得到明显下降，试验组更为显著（P＜0.05）。试验组HBV DNA转阴率（47.2%）显著高于对照组（31.4%），P＜0.05，试验组HBeAg转阴率（33.3%）及HbeAg血清转换率（25.7%）虽高于对照组（19.4%，14.3%），但差异无统计学意义。结论：丁贺与双环醇联合应用治疗慢性乙型肝炎在肝功能学方面取得较好疗效。 　　【关键词】丁贺；双环醇；慢性乙型肝炎 　　 　　【Abstract】Objective: adefovir dipivoxil joint bicyclol treatment of chronic hepatitis b curative effect. Methods selection 71 cases mild-to-moderate chronic hepatitis b patients were randomly divided into two groups, to the test group (36 cases) and daily oral adefovir dipivoxil (shandong LuKang Calvin hin, commodity production DingHe, hereinafter referred to as the name, and DingHe) 10mg daily oral bicyclol (Beijing union production), the control group 35 examples, 150mg per DingHe 10mg only give oral medication, two groups are continuous, 48 weeks observed before and after treatment serum amino transferase level and virology sign of change; Results 2 groups of serum amino transferase both will be housed declined obviously, and more significantly (P 0.05). 4.75%more HBV DNA, shade rate was significantly higher than the control group (47.2%) (31.4%), P 0.05 group a, turn rate HBeAg HBeAg serum (33.3%) and conversion (25.7%) is higher than that of the control group (19.4%, 14.3%), but the difference was not statistically significant. Conclusion DingHe and bicyclol combined application in the treatment of chronic hepatitis b liver learning has good curative effect. 　　【Key word】DingHe，Bicyclic alcohol， Chronic hepatitis B 　　 　　据2004年卫生统计年鉴显示，我国病毒性肝炎已由2000年的64.91/10万人上升到2003年的68.55/10万人，慢性乙肝患者已达2000多万例，约占人口总数的1.55%，而乙肝病毒表面抗原携带者高达9.8%，人数高达1.2亿左右，所以探讨一种合理的治疗慢性乙型肝炎的方法是我们当务之急。乙肝病毒的感染者，由于机体有一定程度的免疫功能，病毒和机体的免疫系统发生抗原抗体反应，肝细胞受到一定程度的损伤，轻者仅有临床症状，如肝区不适，疲乏无力，食欲减退，重者则谷丙酶反复升高，有E抗原阳性的患者，因为病毒复制比较严重，则极易对他人造成传染，即使患者肝功能正常，病人呈“小三阳”或“大三阳”，患者无明显症状。但如果做肝细胞活检，也会发现肝细胞有变性、水肿、气泡